

Special Issue

Advances in Cancer Immunotherapy

Message from the Guest Editor

Cancer immunotherapy with ICI has strongly changed the treatment of some solid tumors, while ACT with CAR- or engineered-T cells has shown great potential in the treatment of patients with hematologic malignancies. However, despite very encouraging results in a well-defined cohort of cancer patients, these therapies are still endowed with high-grade toxicity that determines the limitations of clinical applications. With a better understanding of the workings of the immune system and the identification of new molecular targets, it is possible to develop safe and effective treatments to enhance specific anti-tumor activity. This Special Issue will highlight the role of different forms of immunotherapy in the challenging scenario of cancer treatment, covering both basic research and clinical aspects that may advance our understanding of this new therapeutic option for cancer patients' refractory to conventional therapies.

Guest Editor

Dr. Daniela Montagna

Immunology and Transplantation Laboratory, Pediatric Clinic,
Fondazione IRCCS Policlinico San Matteo, Piazzale Golgi 2, Pavia, Italy
Department of Sciences Clinic-Surgical, Diagnostic and Pediatric,
University of Pavia, 27100 Pavia, Italy

Deadline for manuscript submissions

closed (21 June 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/83418

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)